On Thursday, Liberty Interactive Group (NASDAQ:QVCA)’s shares inclined 0.83% to $29.28.
Liberty Interactive LLC a partner of Liberty Interactive Corporation ( QVCA), declared a semi-annual interest payment to the holders of its 3.5% Senior Exchangeable Debentures due 2031 (the “Debentures”). The amount of the payment is $17.50 per $1,000 original principal amount of Debentures.
Under the Indenture for the Debentures, the original principal amount of the Debentures is adjusted in an amount equal to each extraordinary distribution made to holders of the Debentures. Thereafter, the adjusted principal amount is further reduced on each successive semi-annual interest payment date to the extent necessary to cause the semi-annual interest payment to represent the payment of an annualized yield of 3.5% of the adjusted principal amount. This latter adjustment, to the extent it is made by reason of a particular extraordinary distribution that results in an adjustment to the principal amount of the Debentures, takes effect on the second succeeding interest payment date after the payment of that extraordinary distribution.
Liberty Interactive Corporation, through its auxiliaries, engages in the video and on-line commerce industries in North America, Europe, and Asia. It markets and sells various consumer products primarily through live televised shopping programs, Websites, and mobile applications.
Qiagen NV (NASDAQ:QGEN)’s shares gained 1.04% to $26.76.
QIAGEN N.V. (QGEN) (QIA.F) plans to release its report on results for the second quarter of 2015 on Wednesday, July 29, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). A conference call is planned for Thursday, July 30, at 15:30 CET / 9:30 ET hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets.
At the end of Thursday’s trade, EXCO Resources Inc (NYSE:XCO)‘s shares dipped -2.72% to $0.804.
EXCO Resources, Inc. (XCO) declared that it will be releasing second quarter 2015 results on Monday, July 27, 2015, before the market opens.
EXCO will host a conference call on Monday, July 27, 2015, at 9:00 a.m. (Central Time) to talk about the contents of this release and respond to questions.
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX), ended its Thursday’s trading session with -3.12% loss, and closed at $64.56.
Pacira Pharmaceuticals, Inc. (PCRX) declared that Aratana Therapeutics, Inc. (PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs.
The randomized, blinded, multicenter pivotal study in dogs undergoing knee surgery demonstrated statistically noteworthy improvements in pain evaluation contrast to placebo at each of the 24-hour intervals up to 72 hours following surgery (P<0.05). Based on current timelines for the FDA approval process, Aratana anticipates startning commercialization of AT-003 in dogs in 2016.
acira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
